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ABSTRACT 
 
Acree LS, Porter CB, Godard MP. The Relation Between 
Physiological Markers of Cardiovascular Health and Quality of Life in 
Heart Failure. JEPonline 2012;15(6):13-22. This cross-sectional study 
examined the associations among functional capacity, ejection 
fraction, and health-related quality of life (HRQoL) in stable heart 
failure patients. Twenty-one stable NYHA Class II and III heart failure 
patients (mean age = 56.9 ± 11.1 yrs; BMI = 28.9 ± 4.2 kg·m-2) 
participated in this study. The subjects underwent cardiopulmonary 
treadmill testing to determine peak oxygen consumption (VO2 peak = 
16.9 ± 5.3 mL·kg-1·min-1) and ventilatory threshold (961.9 ± 308.4 ml).  
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to 
assess HRQoL.  Ejection fraction was assessed by echocardiogram 
(EF = 28.9 ± 8.03%). HRQoL was non-significantly (P>0.05) related to 
VO2 peak (r = 0.221), EF (r = 0.204), and ventilatory threshold (r = 
0.108).  However, the physical limitation domain of the KCCQ was 
independently related (P<0.05) to VO2 peak (r = 0.621) and ventilatory 
threshold (r = 0.555). The physiological markers of cardiovascular 
health were specifically related to the physical limitations domain of 
the KCCQ.  These same markers, however, were not associated with 
overall HRQoL, which suggest that both quantitative and qualitative 
measures may be used to better assess cardiovascular health in heart 
failure patients. 
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INTRODUCTION 
 
Heart failure (HF) is a complex clinical syndrome resulting from impaired ability of the heart to 
distribute blood, either from insufficient ventricular filling or the insufficient ability to eject blood.  
Individuals with HF may demonstrate dyspnea and fatigue (limiting exercise tolerance) and fluid 
retention (leading to pulmonary congestion and edema), which may ultimately lead to a reduction in 
functional status.  Preventing the physiological progression of the disease in addition to maintaining 
the functional capability (i.e., exercise capacity and ventricular function) is a major priority in the 
management of HF.  However, alleviating the symptoms and patient suffering is another area of 
primary concern in the treatment of HF that cannot be overlooked.   
 
Functional capacity (peak oxygen consumption, VO2 peak) and cardiac function (i.e., ejection fraction) 
have long been accepted by allied healthcare professionals as the primary physiological parameters 
used to assess and monitor the progression of HF (11-13,16,24).  From a traditional perspective, in 
order to classify and determine functional status based on symptoms, the New York Heart 
Association (NYHA) classification has been used (1).  This classification (Class I – IV) has provided a 
simple, generic means for relating the patient’s symptoms to disease progression.  Furthermore, 
health-related quality of life (HRQoLs) instruments are becoming more accepted, standardized, and 
precise as measures for a subjective measurement on health status (4,5,9,22).  Given that improving 
quality of life for individuals has continued to gain momentum as a primary goal for exercise 
physiologists and medical professionals, it is imperative that we understand it thoroughly. 
 
Some consensus exists in that physiological domains and symptoms have been related to HRQoL in 
clinical populations (5,9). Green et al. (9) determined a significant relationship between distance 
walked in a 6-min walk test to the HRQoL scores (r2 = 0.48, P<0.001), yet a gap remains in what is 
known about physiological function and how it affects the HRQoL in HF patients.  Therefore, the 
purpose of this investigation was to determine if physiological function (i.e., functional capacity and 
cardiac function) are related to HRQoL, as assessed by the KCCQ, in NYHA class II and III HF 
patients. 
 
METHODS  
Subjects 
This was a cross-sectional study involving 21 individuals (12 males and 9 females, 56.9 ± 11.1 yrs of 
age) who were outpatients at a Medical Center in the Midwestern United States.  All patients were 
clinically diagnosed as having stable (³3 months) NYHA class II or class III HF (as determined by a 
board certified cardiologist) with a documented ejection fraction of less than 40%.  Individuals with 
insulin dependent diabetes or with pulmonary dysfunction or disease (i.e., COPD) were excluded 
from participation in the study.  Prior to the initiation of any testing, the subjects were informed of the 
procedures and risks associated with the study.  The participants then signed an informed consent in 
accordance with the Institutional Review Board. 
 
Procedures 
Determining Heart Function: Echocardiography   
Left ventricular ejection fraction (LVEF) was determined from a two-dimensional echocardiogram 
(Acuson, Aspen; Malvern, PA).  The left ventricular systolic and diastolic function was assessed with 
the subjects in the left lateral position in a resting state.  Specifically, left ventricular endocardial and 
epicardial borders in the left parasternal short-axis view and the apical four-chamber view, from at 
least five high quality frozen end-diastolic (onset of QRS complex) and end-systolic (aortic valve 
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closure) frames were captured for analysis.  The LVEF was calculated using the end-systolic volume 
(ESV) and the end-diastolic volume values (EDV) via the Simpson’s rule algorithm.  
 
Cardiopulmonary Exercise Testing: VO2 Peak Testing  
In order to accurately determine the gases exchanged during the cardiopulmonary exercise testing 
(CPET), a metabolic cart (CardiO2/CP, MedGraphics; St. Paul, MN) was used.  After a warm-up for 
approximately 30 min, the pneumotach and gas analyzers were calibrated before testing each 
subject.  Then, each subject was fitted with a nose clip to seal the nostrils allowing air to only escape 
from the mouth to the metabolic cart for analysis.  The subject was required to remain relaxed in a 
seated position with minimal movements for 2 min so that baseline oxygen consumption (VO2) and 
carbon dioxide production (VCO2) values could be obtained.  The laboratory tester responsible for 
conducting the CPET was blinded to the HRQoL status and LVEF values of each subject.   
 
The CPET was conducted using a Modified Bruce Protocol to exhaustion on a treadmill (Trackmaster, 
MedGraphics; St. Paul, MN) during continuous electrocardiographic monitoring.  At the start of the 
test, the subject was asked to start walking at a comfortable pace completing a brief warm-up.  Each 
subject was encouraged to exercise until exhaustion. The highest VO2 value was recorded as the VO2 
peak value in mL×kg-1×min-1. Throughout the duration of the protocol, heart rate (HR) was recorded 
every minute while blood pressure (BP) and the Rating of Perceived Exertion (RPE) was recorded 
only once during each stage (at ~2:30 of each 3-min stage).  RPE was assessed using the Borg 
rating scale ranging from 6 (lightest level of exertion) to 20 (absolute most difficult level of exertion) 
(6). At the end of the test, the highest of all of the monitored values (HR, BP, and RPE) was 
determined to be the peak value.  All of the tests were terminated due to fatigue.  There were no 
additional clinical symptoms that limited the test for any of the HF subjects.   
 
Anaerobic Threshold 
After the functional capacity test was completed, anaerobic threshold (AT) was calculated from the 
test data.  Using the metabolic cart (CardiO2/CP, MedGraphics; St. Paul, MN), the values for the gas 
exchange ratio (VCO2/VO2) every 10 sec averaged throughout the test were charted on a scatter-plot 
graph. The point at which the curve changed from flat or gently rising to a steeper slope was 
determined to be the AT.  The same experienced reviewer made the visual determination of the AT 
for all of the subjects.   
 
Kansas City Cardiomyopathy Questionnaire 
To assess the HRQoL, each subject completed the Kansas City Cardiomyopathy Questionnaire 
(KCCQ), which is a self-administered 23-item questionnaire (9), prior to the VO2 testing. As previously 
defined, the KCCQ quantifies physical limitation, symptoms, quality of life, social interference, and 
self-efficacy in a heart failure population (9).  Responses were ordered on an adjectival (Likert) scale 
and transformed to a score ranging from 0 to 100, as described by Green et al. (9) to better facilitate 
interpretability and clinical gradation. The questionnaire was scored by assigning each response an 
ordinal value, beginning with 1 for the response that implies the lowest level of functioning and 
summing items within each domain (9).   
 
A clinical summary score is calculated by combining the functional status (physical limitations and 
symptom domains) with the quality of life and social limitation domains.  For our analysis, we use the 
clinical summary score to represent overall HRQoL.  The Kansas City Cardiomyopathy Questionnaire 
(KCCQ) has demonstrated to be a reliable (Clinical summary, a = 0.95) and valid (clinical summary, r2 
= 0.55, P<0.001) HRQoL instrument for HF patients, and has served as a clinically meaningful 
outcome measure in patient management and quality assessment (7). 
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Statistical Analyses 
Means and standard deviations (SD) were calculated for all variables (VO2 peak, LVEF, and HRQoL).  
Independent t-tests were conducted among all variables to detect significant differences in a gender 
comparison.  Additionally, Pearson correlation coefficients were calculated to assess the relationships 
among VO2 values, LVEF, and HRQoL domains.  In an attempt to control for possible influential 
variables on HRQoL (i.e., age), a partial correlation was used to further examine the relationship 
between the physiological parameters and HRQoL.  The overall significance level was set at P<0.05.   
 
RESULTS 
 
Baseline physical and clinical characteristics for the group are presented in Table 1.  As mentioned in 
the inclusion criteria, all subjects were classified as NYHA Class II or III HF (Class II, n = 16; Class III, 
n = 4).  Hemodynamic, metabolic, and echocardiographic results for the subjects are presented in 
Table 2. The scores and domains scored on the KCCQ are depicted in Table 3. Lastly, an 
independent t-test revealed that there were no differences between genders (P>0.05) for all of the 
measured variables.   
 
Table 1. Mean and Standard Deviation Values of the Baseline Physical Characteristics for the Whole 
Group (n = 21) and the Number of Subjects Taking Each Type of Cardiovascular Medication in this 
Study.   
 Mean  
   
Height (cm) 171.8 ± 8.8  
Weight (Kg)     85.3 ± 14.0  
Age (yrs)     56.9 ± 11.1  
Body-Mass Index (BMI)   28.9 ± 4.2  
   
Medication Use Total Number (n) % of Total Sample 
   ACE Inhibitor 19   90% 
   ATII Antagonist 1    5% 
   Beta Blocker   21 100% 
   Diuretic  19   90% 
   Calcium Channel Blocker  2   10% 
   Nitrate  8    38% 
   Anti-Coagulant   15    71% 
   Antiarrhythmic  13    62% 
  
ACE = Angiotensin Converting Enzyme; ATII = Angiotensin Two.  
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Table 2. Mean and Standard Deviation Values for all Measured Variables in the Functional Capacity  
and Hemodynamics Testing for the Total Sample (n = 21).   
  Mean 
Functional Capacity Component  
   Relative VO2 peak (mL·kg-1·min-1) 16.9 ± 5.3 
   Absolute VO2 peak (mL·min-1) 1440.8 ± 517.8 
   Anaerobic Threshold (mL·min-1)   961.9 ± 308.4 
      % of Peak VO2  64.9 ± 8.8 
   Heart Rate at Peak Exercise (beats·min-1) 125 ± 22 
   Systolic Blood. Press. at Peak Ex (mmHg) 149 ± 28 
   Diastolic Blood Press. At Peak Ex (mmHg)    66 ± 10 
   Rating of Perceived Exertion at Peak  17 ± 2 
   Time of Exercise (sec)    659.8 ± 213.5 
Cardiac Function  
   Ejection Fraction (%)  28.9 ± 8.0 
  
 
 
Table 3. Mean and Standard Deviation Values for the Health-Related Quality of Life (HRQoL) 
Summary Scores from the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the Total Sample 
(n = 21).   
HRQoL (KCCQ)  Mean 
   Clinical Score 70.2 ± 17.9 
   Physical Limitations 68.7 ± 18.8 
   Self-Efficacy 84.6 ± 20.1 
   Combined Symptoms 72.0 ± 20.9 
   Social Limitations 63.5 ± 27.0 
   Quality of Life 66.2 ± 22.9 
 
 
Pearson correlation coefficients among the physiological measures and the quality of life domains are 
presented in Table 4.  Left ventricular ejection fraction and relative VO2 peak demonstrated non-
significant (P>0.05) correlations with each of the quality of life domains. However, the physical 
limitation domain did demonstrate a significant correlation with absolute VO2 peak (r = 0.45, P=0.039) 
and anaerobic threshold (r = 0.467, P=0.044). Additionally, left ventricular ejection fraction 
demonstrated non-significant relationships (P>0.05) with VO2peak values and anaerobic threshold.   
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Table 4.  Correlations Among VO2 Variables, EF, and QoL Domains in Heart Failure Patients.   
Variables  
Relative         
VO2peak 
Absolute 
VO2peak 
Anaerobic 
Threshold 
Ejection  
Fraction 
   Clinical Score  0.010 0.236 0.245 0.257 
   Physical Limitations  0.260 0.453* 0.467* 0.211 
   Self-Efficacy  0.159 0.052 -0.009 -0.096 
   Combined Symptoms  0.202 0.002 0.009 0.254 
   Social Limitations  -0.010 0.028 0.042 0.367 
   Quality of Life  0.221 0.067 0.108 0.204 
   Ejection Fraction   0.316 0.328 0.030 -- 
*Denotes a significant correlation between variables (P<0.05).   
 
An age-adjusted correlation was used to examine the relationship between functional capacity, EF, 
and HRQoL among the subjects.  The results are presented in Table 5.  The relationship between the 
EF and the quality of life domains remained non-significant (P>0.05).  The relative VO2peak was found 
to significantly correlate with the physical limitations domain (r = 0.483, P=0.042).  Additionally, 
adjusting for age strengthened the correlations between the physical limitations and absolute VO2peak  
(r = 0.621, P=0.006) and anaerobic threshold (r = 0.555, P=0.012). 
 
Table 5.  Age-Adjusted Correlations Among VO2 Variables, EF, and QoL Domains in HF Patients. 
Variables  
Relative 
VO2peak 
Absolute 
VO2peak 
Anaerobic 
Threshold 
Ejection 
Fraction 
   Clinical Score  0.246 0.431 0.381 0.296 
   Physical Limitations  0.483* 0.621** 0.555* 0.227 
   Self-Efficacy  0.263 0.042 0.079 0.053 
   Combined 
Symptoms  0.006 0.171 0.131 0.306 
   Social Limitations  0.013 0.027 0.094 0.351 
   Quality of Life  0.131 0.008 0.006 0.169 
   Ejection Fraction   0.095 0.114 0.012 -- 
*Denotes a significant correlation between variables (P<0.05).  **Denotes a significant correlation 
between variables (P<0.01).   
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DISCUSSION 
 
In this investigation, we examined the relations between peak functional capacity, cardiac function 
and HRQoL in a stable HF population with advanced symptoms and specifically determined the 
contribution of the hemodynamic and metabolic parameters to the patient’s HRQoL. The primary 
findings revealed that: (1) the functional capacity (VO2 peak) and HRQoL were not significantly 
related in this HF population; and (2) the cardiac function, as measured by the echocardiographic EF, 
was not related to HRQoL or peak functional capacity as measured by the peak oxygen consumption 
method. 
 
The functional capacity values obtained in this study were not unexpected with the average VO2 peak 
(16.9 ± 5.3 mL×kg-1×min-1) values reported earlier (1). The anaerobic threshold, which defines when 
ventilation demands exceed what is produced aerobically (12,20), was measured to ensure that the 
termination of the exercise test was because of exhaustion instead of a motivational influence.  In the 
current study, the anaerobic threshold was obtained from 90% of the sample and averaged 11.2 
mL×kg-1×min-1 (64% of the average VO2 peak), which accurately reflects previously reported values 
(12,15,16,24). The anaerobic threshold may represent metabolic efficiency (ability to exercise) at a 
given intensity of physical activity more appropriately in HF patients, since a true VO2 max cannot be 
achieved due to lack of motivation or physical limitations (16). The anaerobic threshold may be used 
to assess disease progression and/or severity, as it provides a useful index of change after an 
intervention (13) with low inter-observer variability and good reproducibility (17,20,22).   
 
The direct assessment of VO2 peak during exercise allows for a more accurate measurement of work 
performed and capacity to do work in a setting where the work intensity of a patient is pushed beyond 
levels of personal comfort (16).  In the present study, using maximal force work capacity with graded 
exercise in conjunction with the KCCQ, the correlation seen between the voluntary maximal 
performance defined by the 6-min walk (i.e., voluntary functional capacity) and the KCCQ (9) could 
not be established.  However, the significant relationship between the physical limitation domain and 
the anaerobic threshold (r = 0.555, P=0.012) offers a new, physiologically objective, parameter of 
functional capacity reflected by the KCCQ questionnaire. Therefore, this revelation could add an 
advantage to the employment of the KCCQ in the management of HF, as the anaerobic threshold has 
been shown to have a high prognostic value for increasing risk of early death in HF patients (8). 
 
Although the subjects’ LVEF responses were low (28.9 ± 8.0%), they were typical for the HF patient 
population (7,11,13).  As hypothesized, the LVEF did not correlate significantly with the subjects’ 
functional capacity (P=0.16). Interestingly, previous reports also failed to demonstrate a relationship 
between maximal exercise capacity and EF at rest (2,3,7,21) or between the response in EF to 
exercise of different intensities (7). Collectively, these findings support the concept that functional 
capacity and central hemodynamics are not dependent upon one another. 
 
Like the functional capacity values, the cardiac function was not correlated with HRQoL scores from 
the KCCQ (P=0.37). Although we had hypothesized that a significant correlation would be 
established, HF patients have demonstrated a poor correlation between symptomatic status (i.e., 
HRQoL) and left ventricular EF.  This finding suggests that the influence of HRQoL may not depend 
strongly upon the most easily obtained clinical marker of ventricular function (EF), but may be 
dependent on more complex or less easily measured set of physiologic or psychological parameters.  
 
The KCCQ prognostic value has recently been confirmed in a population of patients with ACE 
inhibitors and beta blockers with or without aldosterone blockade who were not subjected to graded 
or voluntary peak exercise studies (19). The prognostic value of the VO2 peak test in congestive HF 
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was initially established in patients without beta blocker therapy. The presence of beta blocker 
therapy has been postulated to have a confounding effort upon the prognostic value of the VO2 peak 
result in patients with HF (18).   
 
Relative to this clinical population, these results provide pertinent insight regarding the relationships 
among these parameters in health assessment.  It should also be noted that the relationship between 
the physiological parameters and the HRQoL persists after adjusting for the wide age range in this 
group of HF patients.  While physical activity levels could have also produced a confounding 
influence, all subjects were for the most part inactive.  Furthermore, in an attempt to stabilize the 
degree of severity in HF, only NYHA class II and III patients participated in the study.  Perhaps, the 
relations would have been more robust if NYHA classes I and IV had been included in this study. 
 
CONCLUSIONS 
 
In summary, this investigation found that HRQoL was not associated with forced peak functional 
capacity or with a measure of resting cardiac function.  Furthermore, eak forced functional capacity 
was not significantly correlated to the resting EF (i.e., an indicator of myocardial dysfunction).  The 
difference between the peak oxygen capacity, which forces the subject to walk at increasing speed 
and grade, and the previously correlated 6-min walk test (9) that allows the subject to select a 
comfortable increase in speed or grade may be the factor that influences the correlation between the 
exercise result and the HRQoL score.   
 
This discordance underscores the importance of assessing and managing cardiovascular health 
through a holistic approach, which should incorporate objective evaluations of functional capacity and 
myocardial function in addition to patient centered HRQoL to obtain a comprehensive assessment of 
functional status and prognosis. 
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